A pulmonary rehabilitation program reduces hospitalizations in chronic obstructive pulmonary disease patients: A cost-effectiveness study.
Ann Thorac Med
; 18(4): 190-198, 2023.
Article
em En
| MEDLINE
| ID: mdl-38058789
ABSTRACT
BACKGROUND:
Although pulmonary rehabilitation (PR) is recommended in patients with chronic obstructive pulmonary disease (COPD), there is a scarcity of data demonstrating the cost-effectiveness and effectiveness of PR in reducing exacerbations.METHODS:
A quasi-experimental study in 200 patients with COPD was conducted to determine the number of exacerbations 1 year before and after their participation in a PR program. Quality of life was measured using the COPD assessment test and EuroQol-5D. The costs of the program and exacerbations were assessed the year before and after participation in the PR program. The incremental cost-effectiveness ratio (ICER) was estimated in terms of quality-adjusted life years (QALYs).RESULTS:
The number of admissions, length of hospital stay, and admissions to the emergency department decreased after participation in the PR program by 48.2%, 46.6%, and 42.5%, respectively (P < 0.001 for all). Results on quality of life tests improved significantly (P < 0.001 for the two tests). The cost of PR per patient and the cost of pre-PR and post-PR exacerbations were 1867.7 and 7895.2 and 4201.9, respectively. The PR resulted in a cost saving of 1826 (total, 365,200) per patient/year, and the gain in QALYs was+0.107. ICER was -17,056. The total cost was <20,000/QALY in 78% of patients.CONCLUSIONS:
PR contributes to reducing the number of exacerbations in patients with COPD, thereby slowing clinical deterioration. In addition, it is cost-effective in terms of QALYs.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Ann Thorac Med
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Espanha